Top

Published in:

01-06-2016 | Commentary

Gaps in life expectancy for people with type 1 diabetes

Author: Lars C. Stene

Published in: Diabetologia | Issue 6/2016

Abstract

Two papers in this issue of Diabetologia present recent trends in life expectancy for people with type 1 diabetes, one using data from an Australian registry (Huo et al, DOI: 10.1007/s00125-015-3857-4), the other, a Swedish registry (Petrie et al, DOI: 10.1007/s00125-016-3914-7). This commentary provides a brief review of the concept of the period life expectancy and complexities regarding applicability to patients, before summarising and discussing the main results of the two papers. In addition, some remaining relevant knowledge gaps are discussed.

Morgan E, Cardwell CR, Black CJ, McCance DR, Patterson CC (2015) Excess mortality in type 1 diabetes diagnosed in childhood and adolescence: a systematic review of population-based cohorts. Acta Diabetol 52:801–807CrossRefPubMed

Lind M, Svensson AM, Kosiborod M et al (2014) Glycemic control and excess mortality in type 1 diabetes. N Engl J Med 371:1972–1982CrossRefPubMed

Harding JL, Shaw JE, Peeters A, Guiver T, Davidson S, Magliano DJ (2014) Mortality trends among people with type 1 and type 2 diabetes in Australia: 1997-2010. Diabetes Care 37:2579–2586CrossRefPubMed

Gagnum V, Stene LC, Sandvik L et al (2015) All-cause mortality in a nationwide cohort of childhood-onset diabetes in Norway 1973-2013. Diabetologia 58:1779–1786CrossRefPubMed

American Diabetes Association (2016) Standards of medical care in diabetes-2016. Diabetes Care 39(Suppl 1):S1–S109

Petrie D, Lung T, Rawshani A et al (2016) Recent trends in life expectancy for people with type 1 diabetes in Sweden. Diabetologia. doi:10.1007/s00125-016-3914-7 PubMed

Huo L, Harding JL, Peeters A, Shaw JE, Magliano DJ (2016) Life expectancy of people with type 1 diabetes in 1997–2010: a national Autralian registry-based cohort study. Diabetologia. doi:10.1007/s00125-015-3857-4

Global Burden of Disease 2013 Study Mortality and Causes of Death Collaborators (2013) Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;385:117–171

Livingstone SJ, Levin D, Looker HC et al (2015) Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008–2010. JAMA 313:37–44CrossRefPubMedPubMedCentral

10.

Orchard TJ, Nathan DM, Zinman B et al (2015) Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA 313:45–53CrossRefPubMedPubMedCentral

11.

Chiang JL, Kirkman MS, Laffel LM, Peters AL (2014) Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care 37:2034–2054CrossRefPubMed

12.

Ezzati M, Obermeyer Z, Tzoulaki I, Mayosi BM, Elliott P, Leon DA (2015) Contributions of risk factors and medical care to cardiovascular mortality trends. Nat Rev Cardiol 12:508–530CrossRefPubMed

Title: Gaps in life expectancy for people with type 1 diabetes
Author: Lars C. Stene
Publication date: 01-06-2016
Publisher: Springer Berlin Heidelberg
Published in: Diabetologia / Issue 6/2016
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-016-3943-2

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Gaps in life expectancy for people with type 1 diabetes

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2016

A short leucocyte telomere length is associated with development of insulin resistance

Recent trends in life expectancy for people with type 1 diabetes in Sweden

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: disease mongering or call to action?

Variants in the FTO and CDKAL1 loci have recessive effects on risk of obesity and type 2 diabetes, respectively

PGE2 receptor EP3 inhibits water reabsorption and contributes to polyuria and kidney injury in a streptozotocin-induced mouse model of diabetes

Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page